{"id":58275,"date":"2024-08-14T00:03:59","date_gmt":"2024-08-14T00:03:59","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/08\/14\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/"},"modified":"2024-08-14T00:03:59","modified_gmt":"2024-08-14T00:03:59","slug":"calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/","title":{"rendered":"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results"},"content":{"rendered":"<div>\n<ul>\n<li><em>Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi\u2019s Adult Adipose Allogeneic (AAA) stem cell innovative programs<\/em><\/li>\n<\/ul>\n<ul>\n<li><em>Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company\u2019s Board of Directors,<\/em> <em>and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board<\/em><\/li>\n<\/ul>\n<ul>\n<li><em>Received a new U.S. patent for the company\u2019s novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccine, strengthening Calidi\u2019s position in developing innovative therapies for advanced solid tumors<\/em><\/li>\n<\/ul>\n<p>SAN DIEGO, Aug.  13, 2024  (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.<\/p>\n<p>\u201cCalidi is making solid progress across our development programs while continuing to innovate and expand our industry-leading position in targeted antitumor virotherapies,\u201d said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. \u201cIn addition, we are proud to have received a new U.S. Patent for our SuperNova technology, further strengthening our IP position as we advance the CLD-201 program into the clinic.\u201d<\/p>\n<p><strong>Second Quarter 2024 and Recent Corporate Developments<\/strong><\/p>\n<ul>\n<li>Announced a $2 million strategic investment in July 2024 by Dr. Ronald Rigor into its new subsidiary, Nova Cell, Inc. (\u201cNova Cell\u201d), to advance Calidi\u2019s Adult Adipose Allogeneic (AAA) stem cell innovative programs. Nova Cell was formed to be a technology service provider that develops innovative stem cell-based products using Calidi\u2019s advanced cellular manufacturing process. Dr. Rigor also invested an additional $1 million into Calidi to further its oncology pipeline of assets. In connection with Dr. Rigor\u2019s investment, he was appointed as a member of Calidi\u2019s Scientific and Medical Advisory Board.<\/li>\n<\/ul>\n<ul>\n<li>Appointed George Peoples, MD, FACS, to the company\u2019s Board of Directors, as a Class II director. Dr. Peoples serves as a Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) and an adjunct Professor of Surgical Oncology at MD Anderson Cancer Center.<\/li>\n<\/ul>\n<ul>\n<li>Appointed Mark Gilbert, MD, to the Calidi Medical Advisory Board. Dr. Gilbert most recently served as the Chief of the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0ZKSvYd0M_Q2CC-PxtG0tT7iEEYoMoGrGVoP-ZQesU5nZnvN2eZGo7zlcpN8G_rGTzCM7H5jexU6PKHSLFviNsTZdhPW7IpZIG-zr7DpmR9RQ0jkohJ0vWQ0WgXECHsm\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Neuro-Oncology Branch\">Neuro-Oncology Branch<\/a>\u00a0at NIH from 2014 to 2024. Under Dr. Gilbert\u2019s leadership, his team of laboratory and clinical investigators conducted groundbreaking research that advanced science in the brain tumor field.<\/li>\n<\/ul>\n<ul>\n<li>Received patent covering novel SuperNova technology platform. The patent covers a composition where cells are incubated with an oncolytic virus for a defined period allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus, by virtue of association of the virus, with the carrier cell. Calidi has shown preclinically the potential of SuperNova to shield the viral payload from the immune system allowing for its delivery to tumor sites. The SuperNova platform is composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.<\/li>\n<\/ul>\n<ul>\n<li>Received $2.5 million gross proceeds during July and August 2024 pursuant to warrant exercises.<\/li>\n<\/ul>\n<p><strong>Second Quarter Financial Results<\/strong><\/p>\n<p>The company reported a net loss of $5.8 million, or $1.40 per share, for the three months ended June 30, 2024, compared to a net loss of $12.5 million, or $14.24 per share, for the same period in 2023.<\/p>\n<p>Research and development expenses were $2.2 million for the three months ended June 30, 2024, compared to $3.2 million for the comparable period in 2023.<\/p>\n<p>General and administrative expenses were $3.6 million for the three months ended June 30, 2024, compared to $3.4 million for the comparable period in 2023.<\/p>\n<p>The company had approximately $0.8 million in cash and $0.2 million in restricted cash as of June 30, 2024, compared to $1.9 million in cash and $0.2 million in restricted cash as of December 31, 2023.<\/p>\n<p><strong>About Calidi Biotherapeutics<\/strong><\/p>\n<p>Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eMDN8AGVN-pdwi-GCyNX3pX2W407PJgIFeQp_zD9699bgx7pcBaFFR7CO9fbB2SGv4FRY6_6Q5G59Ktt_X5x4RQFb3059nbt1JVyeEW-Iqg=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>www.calidibio.com<\/strong><\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023, on Form S-1 filed on January 29, 2024, as amended on February 7, 2024, on Form 10-K filed on March 15, 2024, and Final Prospectus filed on April 17, 2024.<\/p>\n<p><u>For Investors and Media:<\/u><\/p>\n<p>Stephen Thesing<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x5ctIWzp5Pm6SsRLP6jQsrm87dXc_gSdzM2Cdc2TH5wevPKC9NPfubvspuQLATp63UNlggCth_BRp6e5piqbzMloDfZn-vWIY_n06dVbuns=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"IR@Calidibio.com\">IR@Calidibio.com<\/a><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"9\" style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>CALIDI BIOTHERAPEUTICS, INC.<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">(<em>In thousands except for par value data<\/em>)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>June 30, 2024<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>December 31, 2023<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>(Unaudited)<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:64%; width:64%; min-width:64%;;vertical-align: bottom ; \"><strong>ASSETS<\/strong><\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:15%; width:15%; min-width:15%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:15%; width:15%; min-width:15%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">CURRENT ASSETS<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Cash<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">836<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,949<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Prepaid expenses and other current assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">789<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,354<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total current assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,625<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,303<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">NONCURRENT ASSETS<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Machinery and equipment, net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,061<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,270<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Operating lease right-of-use assets, net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">3,518<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,073<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other noncurrent assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">227<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">373<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">TOTAL ASSETS<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">6,431<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10,019<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">CURRENT LIABILITIES<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accounts payable<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,460<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,796<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party accounts payable<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">87<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">81<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accrued expenses and other current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">3,236<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">4,896<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party accrued expenses and other current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">504<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">536<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Term notes payable, net of discount, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">233<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">529<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party term notes payable, net of discount, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,539<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">278<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party bridge loan payable, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">211<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party other current liability<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">597<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Finance lease liability, current<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">68<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">81<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Operating lease right-of-use liability, current<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,117<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,035<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">13,052<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10,232<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">NONCURRENT LIABILITIES<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Operating lease right-of-use liability, noncurrent<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,461<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">3,037<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Finance lease liability, noncurrent<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">180<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">216<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Convertible notes payable, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,925<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Warrant liability<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">524<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">623<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party warrant liability<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">41<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">48<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party term notes payable, net of discount, including accrued interest<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">2,060<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other noncurrent liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">1,500<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Related party other noncurrent liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">538<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">TOTAL LIABILITIES<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">18,183<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">18,254<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">STOCKHOLDERS\u2019 DEFICIT<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(11,752<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(8,235<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">6,431<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10,019<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\"><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>CALIDI BIOTHERAPEUTICS, INC.<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><em>(In thousands, except per share data)<\/em><\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"6\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>Three Months Ended June 30,<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>2024<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>2023<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"6\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>(Unaudited)<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>OPERATING EXPENSES<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:64%; width:64%; min-width:64%;;vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Research and development<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:15%; width:15%; min-width:15%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,167<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">)<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:15%; width:15%; min-width:15%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(3,177<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">General and administrative<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(3,605<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(3,360<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; \">Total operating expense<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,772<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(6,537<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Loss from operations<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,772<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(6,537<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>OTHER INCOME (EXPENSES), NET<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Interest expense<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(108<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(98<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Interest expense \u2013 related party<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(165<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(208<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Change in fair value of debt, other liabilities, and derivatives<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">86<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(1,074<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Change in fair value of debt, other liabilities, and derivatives \u2013 related party<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">9<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,773<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Series B convertible preferred stock financing costs \u2013 related party<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(2,680<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Grant income<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">181<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">889<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other income (expense), net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">10<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(16<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; \">Total other income (expenses), net<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">13<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,960<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>LOSS BEFORE INCOME TAXES<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,759<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(12,497<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Income tax provision<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(8<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(4<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>NET LOSS<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(5,767<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(12,501<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Deemed dividend on warrants<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(1,671<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(7,438<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(12,501<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>Net loss per share; basic and diluted<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(1.40<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">(14.24<\/td>\n<td style=\"vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Weighted average common shares outstanding; basic and diluted<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">5,328<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; \">878<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2NjYzQ0ZGMtNWEzOC00ZTI0LTk4MDAtMDc4Y2Y5YjU0YzBhLTEyMDU0MDc=\/tiny\/Calidi-Biotherapeutics-Inc.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi\u2019s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company\u2019s Board of Directors, and the addition of [&#8230;]\n","protected":false},"author":1,"featured_media":58276,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-58275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results\" \/>\n<meta property=\"og:description\" content=\"Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi\u2019s Adult Adipose Allogeneic (AAA) stem cell innovati\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-14T00:03:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/08\/Calidi-Biotherapeutics-Inc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results\",\"datePublished\":\"2024-08-14T00:03:59+00:00\",\"dateModified\":\"2024-08-14T00:03:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\"},\"wordCount\":1371,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\",\"name\":\"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-08-14T00:03:59+00:00\",\"dateModified\":\"2024-08-14T00:03:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results","og_description":"Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi\u2019s Adult Adipose Allogeneic (AAA) stem cell innovati","og_url":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-08-14T00:03:59+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/08\/Calidi-Biotherapeutics-Inc.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results","datePublished":"2024-08-14T00:03:59+00:00","dateModified":"2024-08-14T00:03:59+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/"},"wordCount":1371,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/","url":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/","name":"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-08-14T00:03:59+00:00","dateModified":"2024-08-14T00:03:59+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/calidi-biotherapeutics-reports-second-quarter-2024-operating-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=58275"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58275\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/58276"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=58275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=58275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=58275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}